Jagsonpal Pharmaceuticals Ltd
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Dec - Copies of newspaper advertisement published on December 05, 2025 informing shareholders regarding opening of special window for Re-lodgement of transfer request of Physical shares.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Nov - That the representatives of Jagsonpal Pharmaceuticals Ltd. will be meeting with the investors/analysts on Tuesday, 25th November 2025,.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
18 Nov - Allotment of 56,571 Equity Shares under the Jagsonpal Pharmaceuticals Limited employee stock option plan 2022.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
7 Nov - Transcript for the jagsonpal pharmaceuticals Limited Q2 FY 2026 earnings call held on November 04, 2025 at 2:00 P.M for discussion of Q2 FY26 Financial …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Nov - Copies of advertisement published on November 05, 2025, providing extracts of Unaudited Financial results of the Company for the quarter and half Year ended September …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT REC
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands